A world where Medicine 3.0 is accessible to everyone, leading to improved healthspan, enhanced performance, and extended longevity.

A new standard in consumer health and healthcare is emerging.  During the 20th Century, medicine used the tools of science and technology to “find and fix” disease.  While this “Medicine 2.0” has profoundly shaped our world for the better, it is also seeing diminishing returns to benefit patients and other stakeholders.  Meanwhile, the healthcare crisis continues to accelerate, with 1 in 3 adults globally suffering from multiple chronic conditions. 

Fortunately, in the 21st Century, a revolutionary set of life and data science tools are emerging that allow us to take an evidence-based approach to medicine, making it predictive, preventive, personalized, and participatory.  We believe that the convergence of this scientific revolution, increasing consumer health consciousness, and the pressures created by the global healthcare crisis will give rise to “Medicine 3.0.” 

To make Medicine 3.0 accessible to everyone, a new generation of companies is urgently needed.  These companies will come from a range of emerging fields defining Medicine 3.0, including bio-measurement technologies, digital health, bioactive compounds, and Precision Health Brands™.

At Cornucopian Capital, we’re supporting this new generation of companies by using long-term capital and our unique capabilities to revolutionize health in the 21st century.

We live in a time of historic possibilities – let’s meet the next great challenge of our time – together.